Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Giovanni Triolo, Annarita Giardina, Marcello Govoni, Antonio Carletto, Tamara Ziglioli, Marco Sebastiani, Gianfranco Ferraccioli, Clodoveo Ferri, Piercarlo Sarzi-Puttini, Costantino Botsios, Valentina Foschi, Elisa Gremese, Ennio Giulio Favalli, Fabiola Atzeni, Elena Frati, Florenzo Iannone, Antonio Marchesoni, Giovanni Lapadula, Mauro Galeazzi, Leonardo PunziRoberto Gerli, Roberto Giacomelli, Paola Cipriani, Domenico Biasi, Fausto Salaffi, Roberto Gorla, Stefania Gasparini

    Risultato della ricerca: Articlepeer review

    112 Citazioni (Scopus)

    Abstract

    Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register.METHODS:The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN).RESULTS:176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-years (95% CI 25.2-38.3): 23.7/1000 patient-years (95% CI 13.1-34.2) on ADA; 12.8/1000 patient-years (95% CI 6.3-19.4) on ETN and 65.1/1000 patient-years (95% CI 48.4-81.8) on IFN. The risk was higher in the first than in the second year of treatment, but this difference was not statistically significant (p=0.08) (38.9% of the SIs were recorded in the first 12months of treatment). The risk of SI was significantly different among the three treatment groups (p<0.0001). Multivariate models confirmed that the use of steroids (p<0.046), concomitant DMARD treatment during anti-TNF therapy (p=0.004), advanced age at the start of anti-TNF treatment (p<0.0001), and the use of IFN or ADA rather than ETN (respectively p<0.0001 and p=0.023) were strong and statistically significant predictors of infection.CONCLUSIONS:Anti-TNF therapy is associated with a small but significant risk of SI that is associated with the concomitant use of steroids, advanced age at the start of anti-TNF treatment, and the type of anti-TNF agent.
    Lingua originaleEnglish
    Numero di pagine0
    RivistaAutoimmunity Reviews
    VolumeEpub ahead of print
    Stato di pubblicazionePublished - 2012

    All Science Journal Classification (ASJC) codes

    • ???subjectarea.asjc.2700.2723???
    • ???subjectarea.asjc.2400.2403???

    Fingerprint

    Entra nei temi di ricerca di 'Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry.'. Insieme formano una fingerprint unica.

    Cita questo